Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma

Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma
CHICAGO—-Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma patients retreated with single-agent brentuximab vedotin .
Read more on Business Wire via Yahoo! Finance

IBM, IFC launch toolkit for SMEs
BUSINESS solutions provider, IBM Philippines, and World Bank affiliate International Financial Corporation (IFC) are leading the drive to boost support for the small and medium enterprises in the coun read more
Read more on Sun Star

Comments are closed.